SEARCH:   Advanced

Blood, 15 June 2004, Vol. 103, No. 12, pp. 4396-4407. Prepublished online as a Blood First Edition Paper on October 9, 2003; DOI 10.1182/blood-2003-08-2958. This Article Full Text (PDF) All Versions of this Article: 2003-08-2958v1 103/12/4396    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Thomas, D. A Articles by Kantarjian, H. Search for Related Content PubMed PubMed Citation Articles by Thomas, D. A Articles by Kantarjian, H. Social Bookmarking                   What's this? Submitted September 2, 2003 Accepted September 29, 2003 Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Deborah A Thomas*, Stefan Faderl, Jorge Cortes, Susan O'Brien, Francis J Giles, Steven M Kornblau, Guillermo Garcia-Manero, Michael J Keating, Michael Andreeff, Sima Jeha, Miloslav Beran, Srdan Verstovsek, Sherry Pierce, Laurie Letvak, August Salvado, Richard Champlin, Moshe Talpaz, and Hagop Kantarjian Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA Department of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA Department of Blood & Bone Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA Novartis Pharmaceuticals Corp., East Hanover, NJ, USA Department of Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA * Corresponding author; email: debthomas{at}mdanderson.org. Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in refractory/relapsed Ph-positive acute lymphocytic leukemia (ALL). Use of concurrent chemotherapy and imatinib in newly diagnosed Ph-positive ALL was explored. Twenty patients received hyper-CVAD and imatinib followed by imatinib-based consolidation/maintenance therapy. Eleven patients had de novo disease, 4 were primary failures after induction (without imatinib), and 5 were in complete remission (CR) after induction (without imatinib). All 15 patients treated for active disease achieved CR. Ten patients underwent allogeneic stem cell transplant (SCT) in first CR within a median of 3.5 months. One patient relapsed after matched related SCT. The other 9 patients remained alive in CR with median follow-up of 12 months after SCT (range, 1+ to 17+ months). Among 10 patients ineligible for (no donor or older age) or refusing allogeneic SCT, one patient relapsed after one year. Five patients remained alive in continuous CR for a median of 20 months (range, 4+ to 24+ months), with 2 older patients dying in CR at 15 and 16 months of co-morbid conditions. Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Jones, R. Luthra, J. Cortes, D. Thomas, S. O'Brien, C. Bueso-Ramos, S. Hai, F. Ravandi, M. de Lima, H. Kantarjian, et al. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias Blood, December 15, 2008; 112(13): 5190 - 5192. [Abstract] [Full Text] [PDF] J. G. Harb, B. I. Chyla, and C. S. Huettner Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis Blood, April 1, 2008; 111(7): 3760 - 3769. [Abstract] [Full Text] [PDF] M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, K. Nishii, Y. Ueda, M. Takeuchi, S. Miyawaki, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy Haematologica, February 1, 2008; 93(2): 287 - 290. [Abstract] [Full Text] [PDF] O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. A. Larson, G. Rege-Cambrin, J. Radich, A. Hochhaus, A. M. Apanovitch, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood, October 1, 2007; 110(7): 2309 - 2315. [Abstract] [Full Text] [PDF] E. Atallah, J.-B. Durand, H. Kantarjian, and J. Cortes Congestive heart failure is a rare event in patients receiving imatinib therapy Blood, August 15, 2007; 110(4): 1233 - 1237. [Abstract] [Full Text] [PDF] H. Pfeifer, B. Wassmann, A. Pavlova, L. Wunderle, J. Oldenburg, A. Binckebanck, T. Lange, A. Hochhaus, S. Wystub, P. Bruck, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood, July 15, 2007; 110(2): 727 - 734. [Abstract] [Full Text] [PDF] D. P. Kalogianni, V. Bravou, T. K. Christopoulos, P. C. Ioannou, and N. C. Zoumbos Dry-reagent disposable dipstick test for visual screening of seven leukemia-related chromosomal translocations Nucleic Acids Res., February 28, 2007; 35(4): e23 - e23. [Abstract] [Full Text] [PDF] J.-M. Ribera, J.-J. Ortega, A. Oriol, P. Bastida, C. Calvo, J.-M. Perez-Hurtado, M.-E. Gonzalez-Valentin, V. Martin-Reina, A. Molines, F. Ortega-Rivas, et al. Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial J. Clin. Oncol., January 1, 2007; 25(1): 16 - 24. [Abstract] [Full Text] [PDF] D. A. Thomas Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges Hematology, January 1, 2007; 2007(1): 435 - 443. [Abstract] [Full Text] [PDF] W. Stock and N. L. Seibel Acute lymphoblastic leukemia and lymphoblastic lymphoma ASH Self-Assessment Program, January 1, 2007; 2007(1): 253 - 264. [Full Text] [PDF] D. A. Thomas, H. M. Kantarjian, J. Cortes, S. Faderl, F. Giles, G. Garcia-Manero, W. Wierda, A. Ferrajoli, F. Ravandi-Kashani, S. Verstovsek, et al. Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 284 - 284. [Abstract] [PDF] S. Jeha, F. Behm, D. Pei, J. T. Sandlund, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, N. Hijiya, S. C. Howard, C. Cheng, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia Blood, November 15, 2006; 108(10): 3302 - 3304. [Abstract] [Full Text] [PDF] B. Wassmann, H. Pfeifer, N. Goekbuget, D. W. Beelen, J. Beck, M. Stelljes, M. Bornhauser, A. Reichle, J. Perz, R. Haas, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) Blood, September 1, 2006; 108(5): 1469 - 1477. [Abstract] [Full Text] [PDF] H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med., June 15, 2006; 354(24): 2542 - 2551. [Abstract] [Full Text] [PDF] M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, T. Kobayashi, Y. Ueda, M. Takeuchi, S. Miyawaki, et al. High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group J. Clin. Oncol., January 20, 2006; 24(3): 460 - 466. [Abstract] [Full Text] [PDF] C.-H. Pui and W. E. Evans Treatment of Acute Lymphoblastic Leukemia N. Engl. J. Med., January 12, 2006; 354(2): 166 - 178. [Full Text] [PDF] S. Chiaretti, A. Guarini, M. S. De Propris, S. Tavolaro, S. Intoppa, A. Vitale, S. Iacobelli, L. Elia, C. Ariola, J. Ritz, et al. ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications Blood, January 1, 2006; 107(1): 197 - 204. [Abstract] [Full Text] [PDF] S. Faderl, K.-A. Do, M. M. Johnson, M. Keating, S. O'Brien, I. Jilani, A. Ferrajoli, F. Ravandi-Kashani, C. Aguilar, A. Dey, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia Blood, December 15, 2005; 106(13): 4303 - 4307. [Abstract] [Full Text] [PDF] D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. Giles, G. Garcia-Manero, S. Kornblau, M. Andreeff, M. Beran, S. Verstovsek, et al. Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1830 - 1830. [Abstract] F. Giles, S. Verstovsek, D. Thomas, S. Gerson, J. Cortes, S. Faderl, A. Ferrajoli, F. Ravandi, S. Kornblau, G. Garcia-Manero, et al. Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia Clin. Cancer Res., November 1, 2005; 11(21): 7817 - 7824. [Abstract] [Full Text] [PDF] E. J. Jabbour, S. Faderl, and H. M. Kantarjian Adult Acute Lymphoblastic Leukemia Mayo Clin. Proc., November 1, 2005; 80(11): 1517 - 1527. [Abstract] [PDF] S. A. Armstrong and A. T. Look Molecular Genetics of Acute Lymphoblastic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6306 - 6315. [Abstract] [Full Text] [PDF] B. Peng and R. Capdeville In Reply: J. Clin. Oncol., June 1, 2005; 23(16): 3857 - 3858. [Full Text] [PDF] R. T. Maziarz Ph+ ALL: another success for imatinib Blood, May 1, 2005; 105(9): 3388 - 3389. [Full Text] [PDF] S. Lee, Y.-J. Kim, C.-K. Min, H.-J. Kim, K.-S. Eom, D.-W. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, May 1, 2005; 105(9): 3449 - 3457. [Abstract] [Full Text] [PDF] M. Towatari, M. Yanada, N. Usui, J. Takeuchi, I. Sugiura, M. Takeuchi, F. Yagasaki, Y. Kawai, S. Miyawaki, S. Ohtake, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood, December 1, 2004; 104(12): 3507 - 3512. [Abstract] [Full Text] [PDF] J. Lee, S. N. Sait, and M. Wetzler Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts Int. Immunol., October 1, 2004; 16(10): 1377 - 1389. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020